After-Hours Stock Movers 01/18: (SOFI) (CNXC) (TGNA) Higher; (CRDF) (ADS) Lower (more...)

January 18, 2022 6:15 PM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

After-Hours Stock Movers

Cardiff Oncology, Inc. (Nasdaq: CRDF) 16.6% LOWER; announced new data from its lead clinical program evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). A subset of these data will be featured in a poster presented by Dr. Heinz-Josef Lenz, principal investigator, USC Norris Comprehensive Cancer Center, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCOGI) on Saturday, January 22, 2022.

SoFi Technologies, Inc. (NASDAQ: SOFI) 10.8% HIGHER; The Office of the Comptroller of the Currency (OCC) today conditionally approved applications from Social Finance Inc. (SoFi) (NASDAQ: SOFI) to create SoFi Bank, National Association (SoFi Bank, N.A.), as a full service national bank headquartered in Cottonwood Heights, Utah. As part of the transaction, SoFi Bank, N.A. will acquire Golden Pacific Bank, National Association, a national bank insured by the Federal Deposit Insurance Corporation.

ADS (NYSE: ADS) 5.9% LOWER; BJ's Wholesale Club (NYSE: BJ) Moving Co-Branded Credit Cards to Capital One (NYSE: COF) in Blow to ADS (NYSE: ADS) - WSJ

Concentrix Corporation (NASDAQ: CNXC) 5% HIGHER; reported Q4 EPS of $2.99, $0.28 better than the analyst estimate of $2.71. Revenue for the quarter came in at $1.47 billion versus the consensus estimate of $1.46 billion. Concentrix Corporation sees FY2022 revenue of $6.45-6.6 billion, versus the consensus of $6.16 billion.

TEGNA (NYSE: TGNA) 4.3% HIGHER; Standard General, Apollo Global (NYSE: APO) Close in on $9B Deal for TEGNA (NYSE: TGNA).

Revance Therapeutics, Inc. (Nasdaq: RVNC) 4.2% HIGHER; received the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for DaxibotulinumtoxinA for Injection for glabellar lines. The Type A meeting was held on December 15, 2021.

Venus Concept Inc. (NASDAQ: VERO 2.3% HIGHER; received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Venus BlissMAX device (BlissMAX) in the United States.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

After-Hours Movers, FDIC, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, FDA